The road to HIV elimination
Celebrating Burnet excellence: Gust-McKenzie Medal and Frank Fenner Award
Lingering SARS-CoV-2 infection may be driving long COVID
New international grants to fuel next-generation malaria vaccines
Research Reports + Policy Briefs
IMPACT Magazine
Events
Research Articles
How Science Matters Podcast
Study at Burnet
Towards a cure for long COVID: the strengthening case for persistently replicati...
Exploring the Feasibility and Acceptability of Technological Interventions to Pr...
A systematic review and meta-analysis of heat exposure impacts on maternal, feta...
The role and value of counsellors in the treatment journeys of people with tuber...
Vaccines
Diagnostics
Therapeutics
Antibody Platforms
Australia
Papua New Guinea
Myanmar
People of Burnet
Leadership
Burnet Partners
Board Members
Current Appeal
Monthly Giving
Trusts + Foundations
Corporate Supporters
Giving in Wills + Bequests
Supporter Stories
About Us
Careers
History
Annual + Financial Reports
Burnet Institute is developing platforms to enhance efficacy of antibodies, Fc-fusion proteins, and antibody-like biologics that have potential application in oncology, infectious disease and immunological conditions.
Find us at BIO 2024 this June.
A hexamerising technology that transforms the potency of monoclonal antibodies (mAb), Fc fusion prot...